Agilon (AGL) Reports Q4 Earnings: What Key Metrics Have to Say

For the quarter ended December 2023, Agilon Health (AGL) reported revenue of $1.06 billion, up 53.1% over the same period last year. EPS came in at -$0.41, compared to -$0.14 in the year-ago quarter.

The reported revenue represents a surprise of +0.72% over the Zacks Consensus Estimate of $1.05 billion. With the consensus EPS estimate being -$0.28, the EPS surprise was -46.43%.

While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.

Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.

Here is how Agilon performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:

  • Average Medicare Advantage membership: 391,700 versus 390,592 estimated by three analysts on average.
  • Direct Contracting beneficiaries (ACO REACH): 89,300 compared to the 86,350 average estimate based on two analysts.
  • Medicare Advantage Members: 388,400 compared to the 386,200 average estimate based on two analysts.
  • Revenues- Medical services: $1.05 billion versus $1.05 billion estimated by six analysts on average. Compared to the year-ago quarter, this number represents a +52.9% change.
  • Revenues- Other operating: $2.53 million versus $2.50 million estimated by six analysts on average. Compared to the year-ago quarter, this number represents a +175.6% change.
View all Key Company Metrics for Agilon here>>>

Shares of Agilon have returned +3.5% over the past month versus the Zacks S&P 500 composite's +3.8% change. The stock currently has a Zacks Rank #4 (Sell), indicating that it could underperform the broader market in the near term.

Just Released: Zacks Top 10 Stocks for 2024

Hurry – you can still get in early on our 10 top tickers for 2024. Hand-picked by Zacks Director of Research, Sheraz Mian, this portfolio has been stunningly and consistently successful. From inception in 2012 through November, 2023, the Zacks Top 10 Stocks gained +974.1%, nearly TRIPLING the S&P 500’s +340.1%. Sheraz has combed through 4,400 companies covered by the Zacks Rank and handpicked the best 10 to buy and hold in 2024. You can still be among the first to see these just-released stocks with enormous potential.

See New Top 10 Stocks >>

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

Agilon Health, Inc. (AGL) : Free Stock Analysis Report

To read this article on click here.

Zacks Investment Research

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.


More Related Articles

Info icon

This data feed is not available at this time.

Sign up for the TradeTalks newsletter to receive your weekly dose of trading news, trends and education. Delivered Wednesdays.